Rituximab cancer drug bottles

Rituximab cancer drug bottles

M625/1540 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 62.9MB

Downloadable file size: 2.0MB

Price image Pricing

Please login to use the price calculator


Restrictions: Editorial use only

Caption: Rituximab cancer drug. 100 milligram and 500 milligram bottles and packaging of liquid concentrate rituximab, a cancer drug marketed as MabThera. Rituximab is a monoclonal antibody used to treat B cell non-Hodgkin's lymphoma and B cell leukaemia. B cells are a type of white blood cell. The antibody works by binding to CD20 receptors on the surface of the B cells, which flags them for destruction by the body's immune system. This clears the B cells, including the cancerous cells, from the blood, allowing them to be replaced with healthy cells produced by stem cells in the bone marrow. Rituximab may also be used to treat autoimmune diseases that result from the proliferation of B cells, to help prevent rejection of transplanted organs, and also to treat rheumatoid arthritis.

Release details: Model release not required. Property release not required.

Keywords: 100mg, 10ml, 500mg, 50ml, b cell leukaemia, bottle, bottles, box, boxes, cancer drug, cd20 receptor, chemotherapy, concentrate, drug, drugs, healthcare, label, leukemia, liquid, lymphoma, mabthera, medical, medicine, monoclonal antibody, non-hodgkin's lymphoma, oncology, packaging, pharmaceutic, pharmaceutical, phial, prescription drug, rheumatoid arthritis, rituximab, sealed, solution, still life, still-life, treatment, vial, vials

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.